DexCom's revised FY24 sales guidance in the Q2 earnings call led to a $18bn valuation reset. Read why I think DXCM stock is a ...

If a patient receives a continuous glucose monitor device through their medical benefit, they may be more adherent and may ...

These devices are increasingly popular in diabetes management and health monitoring. As previously announced, Trinity Biotech has entered into a non-binding Letter of Intent with Bayer for the launch ...

Real-world data showed reductions in healthcare resource utilization and improved glycemic control over 1 year with ...

DexCom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, announced today the launch of the third season of Dexcom U, the company's ...

Eversense 365 is said to be the world's first one-year CGM system, offering a new long-term solution for diabetes management.

addressing one of the major drawbacks of existing CGM devices, deemed invasive due to the requirement of a needle inserted ...

Senseonics (NYSE:SENS) announced today that it received FDA clearance for its next-generation Eversense 365 CGM system.

The U.S. FDA cleared Senseonic Holdings Inc.’s Eversense 365, the first continuous glucose monitor to last a full year with a single sensor rather than the 10 days to two weeks typical for wearable ...

Eversense 365 is a fully-implantable CGM with a 365-day sensor, making it the first 1-year CGM option for diabetes management ...

Patients living with diabetes who use continuous glucose monitoring devices had 35% lower total cost of care and 23% higher device adherence when therapy was provided through a medical vs. pharmacy be ...

Senseonics and Ascensia Diabetes Care have announced that the U.S. Food and Drug Administration has cleared the next-generation Eversense 365 CGM, the first one-year CGM system ...